Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 576

1.

Treatment of early Parkinson's disease. Part 2.

Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D.

Eur Neurol. 2009;61(4):206-15. doi: 10.1159/000197104. Epub 2009 Jan 29. Review.

2.

Treatment of early Parkinson's disease. Part 1.

Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D.

Eur Neurol. 2009;61(4):193-205. doi: 10.1159/000197103. Epub 2009 Jan 29. Review.

3.

Treatment options for early Parkinson's disease.

Stacy M, Brownlee HJ.

Am Fam Physician. 1996 Mar;53(4):1281-7. Review.

PMID:
8629572
4.

Future therapies for Parkinson's disease.

Hauser RA, Lyons KE.

Neurol Clin. 2004 Oct;22(3 Suppl):S149-66. Review. No abstract available.

PMID:
15501363
5.

[Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].

Kuhn W, Müller T.

Fortschr Neurol Psychiatr. 1997 Aug;65(8):361-74. Review. German.

PMID:
9378449
6.

Recent developments in the pharmacological treatment of Parkinson's disease.

Tuite P, Riss J.

Expert Opin Investig Drugs. 2003 Aug;12(8):1335-52. Review.

PMID:
12882620
7.

Early pharmacologic treatment in Parkinson's disease.

Hauser RA.

Am J Manag Care. 2010 Mar;16 Suppl Implications:S100-7. Review.

8.

Current strategies in the treatment of Parkinson's disease and a personalized approach to management.

Diaz NL, Waters CH.

Expert Rev Neurother. 2009 Dec;9(12):1781-9. doi: 10.1586/ern.09.117. Review.

PMID:
19951137
9.
10.
11.

The comparative effects of medical therapies for Parkinson's disease.

Horn S, Stern MB.

Neurology. 2004 Oct 12;63(7 Suppl 2):S7-12. Review. No abstract available.

PMID:
15477585
12.

The evolution of pharmacological treatment for Parkinson's disease.

Almeida QJ, Hyson HC.

Recent Pat CNS Drug Discov. 2008 Jan;3(1):50-4. Review.

PMID:
18221241
13.

Dopamine agonists in Parkinson's disease.

Yamamoto M, Schapira AH.

Expert Rev Neurother. 2008 Apr;8(4):671-7. doi: 10.1586/14737175.8.4.671. Review.

PMID:
18416667
14.

Drug selection and timing of initiation of treatment in early Parkinson's disease.

Schapira AH, Olanow CW.

Ann Neurol. 2008 Dec;64 Suppl 2:S47-55. doi: 10.1002/ana.21460.

PMID:
19127579
15.

Levodopa-related wearing-off in Parkinson's disease: identification and management.

Pahwa R, Lyons KE.

Curr Med Res Opin. 2009 Apr;25(4):841-9. doi: 10.1185/03007990902779319 . Review.

PMID:
19228103
16.

Novel pharmacological targets for the treatment of Parkinson's disease.

Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G.

Nat Rev Drug Discov. 2006 Oct;5(10):845-54. Review.

PMID:
17016425
17.

Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

Olanow CW.

Neurology. 2009 Feb 17;72(7 Suppl):S59-64. doi: 10.1212/WNL.0b013e318199068b. Review.

PMID:
19221316
18.

Parkinson's disease therapy: treatment of early and late disease.

Jankovic J.

Chin Med J (Engl). 2001 Mar;114(3):227-34. Review.

PMID:
11780303
19.

Dopamine agonists and neuroprotection in Parkinson's disease.

Olanow CW, Jenner P, Brooks D.

Ann Neurol. 1998 Sep;44(3 Suppl 1):S167-74. Review.

PMID:
9749590
20.

Emerging drugs for Parkinson's disease.

Morgan JC, Sethi KD.

Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17. Review.

PMID:
16939381

Supplemental Content

Support Center